TARS
Tarsus Pharmaceuticals, Inc.
TARS offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
UNH
UnitedHealth Group Incorporated
UNH has the edge over TARS overall, supported by stronger modeled upside and lower modeled downside.
TARS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Healthy | |
| Unavailable |
TARS's revenue and cash flow are currently healthy, but its profitability is weak. There isn't enough data to rate its balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
TARS PE Valuation
TARS has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
TARS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
TARS has the edge over UNH on the outlook, with more favorable revenue expectations.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
TARS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$15.16 | -$13.17 |
| Q2 2026 | -$1.06 | +$1.24 |
| Q1 2026 | -$1.11 | +$1.59 |
| Q4 2025 | -$1.59 | +$1.48 |
| Q3 2025 | -$1.99 | +$1.80 |
| Q2 2025 | -$2.30 | +$2.16 |
| Q1 2025 | -$2.70 | +$2.05 |
| Q4 2024 | -$3.07 | +$1.55 |
TARS lost $15.16 per share over the past year, a bigger loss than the year before.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over TARS on earnings quality, reporting a profit while its opponent remains loss making.
TARS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $194.6M | +64% |
| Q2 2026 | $173.9M | +69% |
| Q1 2026 | $162.1M | +107% |
| Q4 2025 | $151.7M | +128% |
| Q3 2025 | $118.7M | +147% |
| Q2 2025 | $102.7M | +152% |
| Q1 2025 | $78.3M | +184% |
| Q4 2024 | $66.4M | +408% |
TARS has the edge over UNH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -340% | -328 points |
| Q2 2026 | -11% | +10 points |
| Q1 2026 | -3.8% | +30 points |
| Q4 2025 | -5.3% | +32 points |
| Q3 2025 | -12% | +40 points |
| Q2 2025 | -22% | +60 points |
| Q1 2025 | -34% | +103 points |
| Q4 2024 | -37% | +303 points |
TARS's operating margin was −340% last quarter, down 328 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over TARS on profitability, with a higher operating margin.
TARS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$7.2M | -144% |
| Q2 2026 | $57.2M | +$87.5M |
| Q1 2026 | -$30.5M | -$9.2M |
| Q4 2025 | $13M | +$35.2M |
| Q3 2025 | $16.3M | +$25.3M |
| Q2 2025 | -$30.4M | -$14.9M |
| Q1 2025 | -$21.2M | +$16.7M |
| Q4 2024 | -$22.3M | +$17.1M |
TARS's free cash flow has turned positive after six years mostly in the red: $32M over the past year.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH still generates free cash flow, though less than at its 2022 peak: $22.8B over the past year.
TARS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7% | +3M shares |
| 1 year | +9% | +3.8M shares |
| 3 years | +52% | +15.8M shares |
| 5 years | +125% | +25.8M shares |
| Available history | +326% | +35.5M shares |
TARS has 46M diluted shares, up 9% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2020 | $1,000 |
| Q1 2020 | $27,000 |
| Q4 2019 | — |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over TARS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
TARS Net Leverage
TARS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
TARS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.0 | Neutral |
| Stochastic | 44.3 | Neutral |
TARS's weekly RSI is 56 (neutral) and its Stochastic is 44 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
TARS PE vs Healthcare Sector
TARS has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
TARS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $72.3 | 6.3% above |
| 20 week MA | $70.3 | 9.4% above |
| 50 week MA | $69.2 | 11% above |
| 100 week MA | $60.9 | 26% above |
| 200 week MA | $42.9 | 79% above |
TARS has the edge over UNH on trend strength, trading above more of its moving averages.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 9.3% below its 200-week average.
TARS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $20.6 | $44.0 | +114% |
| 2021 | $44.0 | $25.9 | -41% |
| 2022 | $25.9 | $14.5 | -44% |
| 2023 | $14.5 | $20.3 | +40% |
| 2024 | $20.3 | $55.0 | +172% |
| 2025 | $55.0 | $81.8 | +49% |
| 2026 YTD | $81.8 | $76.9 | -6% |
TARS's yearly returns have swung widely, from +172% in 2024 to −44% in 2022. It's down 6% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over TARS on returns for 2026, with the stronger performance.